Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 389-390

  Berruti, Alfredo ^a   Sculli, C M ^a   Ragni, F ^a   Porpiglia, F ^a   Tampellini, M ^a   Gorzegno, G ^a   Priola, A M ^a   Dogliotti, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FENTANYL; GEMCITABINE; MORPHINE; VITAMIN D; ZOLEDRONIC ACID;

AGED; AMBULATORY CARE; ANALGESIA; BONE METASTASIS; BONE PAIN; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HUMAN; HYPOCALCEMIA; LETTER; LONG TERM CARE; MEDICATION ERROR; PRIORITY JOURNAL; TREATMENT INDICATION; TUMOR LOCALIZATION; UROGENITAL TRACT CANCER;

EID: 60549093407     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn720     Document Type: Letter

References (3)

1. Daubiné F, Le Gall C, Gasser J et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99: 322-330.
2. Ottewell PD, Monkkonen H, Jones M et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100(16): 1167-1178.
3. Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13: 4482-4486.